Citadel Advisors
VTAE

Citadel Advisors’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Citadel Advisors’s Portfolio VTAE Stock Details VTAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-17,574
Closed -$190K – 8192
2016
Q2 		$190K Sell
17,574
-4,961
-22% -$42.4K ﹤0.01% 5877
2016
Q1 		$149K Sell
22,535
-1,960
-8% -$17.8K ﹤0.01% 5833
2015
Q4 		$443K Buy
+24,495
New +$337K ﹤0.01% 4625
2015
Q1 		– Sell
-27,089
Closed -$451K – 9112
2014
Q4 		$451K Buy
+27,089
New +$396K ﹤0.01% 4869

Other funds holding VTAE

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors's VTAE Position: Q3 2016 in Review

Citadel Advisors sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q3 2016, closing a stake of 17,574 shares — an estimated $190K sold.

Citadel Advisors first reported a position in VTAE in Q4 2014 and held it in 4 quarters. The position peaked at $451K in Q4 2014. 98 funds tracked by Wall St. Rank hold VTAE as of Q3 2016.

  • Citadel Advisors reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q3 2016 after selling out during the quarter.
  • Citadel Advisors sold 17,574 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q3 2016, an estimated $190K.
  • Citadel Advisors first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2014 and held it in 4 quarters.
  • Citadel Advisors's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $451K in Q4 2014.
  • 98 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q3 2016.

Based on Citadel Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.